Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camoteskimab in moderate to severe atopic dermatitis
NCT06436183Phase 2Completed
- Sponsor
- Apollo Therapeutics
- Start
- May 2024
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of camoteskimab in atopic dermatitis (AD), sponsored by Apollo Therapeutics. Started May 2024; status: completed.
02
Drugs
camoteskimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06436183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06436183.